Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
Department of Physical Therapy, Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
J Pediatr Urol. 2024 Aug;20(4):589-595. doi: 10.1016/j.jpurol.2024.03.025. Epub 2024 Mar 26.
To evaluate the possible impact of patients' sacral ratios (SRs) on response to biofeedback (BF) therapy in pediatric patients with lower urinary tract dysfunction (LUTD).
In this retrospective cohort conducted from 2016 to 2018 in our tertiary medical center, we included the medical records of all pediatric patients with LUTD who were nominated for BF due to having abnormal uroflowmetry patterns and simultaneous increase in electromyography (EMG) activity. Ten sessions of weekly animated BF were performed for each patient. All patients underwent a complete urological evaluation, uroflowmetry with simultaneous EMG and post-void residual measurement before and after treatment. SRs were calculated based on plain anteroposterior lumbosacral radiographs. Patients were then divided into normal SR (≥0.74) and low SR (<0.74) and outcomes were compared between them.
Of the total 86 patients included in our study, 48 (55.8%) had a normal SR (≥0.74), while 38 (44.2%) had a low SR (<0.74). Our data revealed that BF therapy significantly improved maximum and average urinary flow rates, urine volume, daytime urinary incontinence, enuresis, urinary urgency and constipation; irrespective of the patients' SRs (all P < 0.001). Our between-groups analyses showed that after the completion of BF, the SR ≥ 0.74 group had significantly higher maximum urinary flow rate (mean difference [95%CI]: 7.7 [5.4, 10.0], P < 0.001) (Figure) and urine volume (mean difference [95%CI]: 49.9 [19.5, 80.4], P = 0.002) and significantly lower diurnal urinary incontinence (4.2% vs. 21.1%, P = 0.020), enuresis (4.2% vs. 18.4%, P = 0.040) and constipation (2.1% vs. 23.7%, P = 0.004) compared to the SR < 0.74 group.
SR has been proposed as a reliable indicator of bony pelvis growth and subsequent lumbosacral neurodevelopment. Additionally, larger SR values are associated with better postoperative sphincter function in children with urological and anorectal malformations. Our results demonstrated that after completion of BF, the normal SR group had a significantly better improvement of some of the uroflowmetry indicators and LUTD-associated symptoms compared to the low SR group.
Our findings implied that although BF therapy is an efficient treatment for children with LUTD, irrespective of their sacral development; children with enhanced sacral development may benefit from better clinical response, especially in terms of LUTD-associated symptoms.
评估患者骶骨比(SR)对生物反馈(BF)治疗小儿下尿路功能障碍(LUTD)患者疗效的可能影响。
本回顾性队列研究于 2016 年至 2018 年在我们的三级医学中心进行,纳入了因异常尿流率模式和同时肌电图(EMG)活动增加而被推荐接受 BF 治疗的所有小儿 LUTD 患者的病历。为每位患者进行 10 次每周动画 BF。所有患者均接受完整的泌尿科评估、尿流率检查,同时进行 EMG 检查和治疗前后残余尿量测量。SR 根据腰骶部前后位平片计算。然后将患者分为正常 SR(≥0.74)和低 SR(<0.74),并比较两组之间的结果。
在我们的研究中,总共纳入了 86 名患者,其中 48 名(55.8%)SR 正常(≥0.74),38 名(44.2%)SR 较低(<0.74)。我们的数据显示,BF 治疗显著改善了最大和平均尿流率、尿量、日间尿失禁、遗尿、尿急和便秘;与患者的 SR 无关(均 P<0.001)。我们的组间分析显示,BF 治疗完成后,SR≥0.74 组的最大尿流率(平均差异 [95%CI]:7.7 [5.4, 10.0],P<0.001)和尿量(平均差异 [95%CI]:49.9 [19.5, 80.4],P=0.002)显著更高,日间尿失禁(4.2% vs. 21.1%,P=0.020)、遗尿(4.2% vs. 18.4%,P=0.040)和便秘(2.1% vs. 23.7%,P=0.004)显著更低,与 SR<0.74 组相比。
SR 已被提出作为骨盆生长和随后的腰骶神经发育的可靠指标。此外,较大的 SR 值与儿童泌尿生殖和肛肠畸形术后括约肌功能的改善有关。我们的结果表明,与低 SR 组相比,BF 治疗完成后,SR 正常组的一些尿流率指标和 LUTD 相关症状有明显改善。
尽管 BF 治疗是小儿 LUTD 的有效治疗方法,与骶骨发育无关;但骶骨发育良好的儿童可能从更好的临床反应中获益,尤其是在 LUTD 相关症状方面。